2001
DOI: 10.1016/s0006-8993(01)02388-5
|View full text |Cite
|
Sign up to set email alerts
|

Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells

Abstract: Nicotine-induced catecholamine (CA) secretion and inward ionic currents were inhibited by the opioid antagonist naloxone in cultured bovine chromaffin cells. Naloxone inhibited nicotine-induced CA secretion, as detected by an on-line real-time electrochemical technique, in a dose-dependent manner (IC(50)=29 microM). In voltage-clamped chromaffin cells, nicotine (10 microM) evoked an average peak inward current of -146 pA that was inhibited by low concentrations of naloxone (42% at 0.1 microM). The antagonist a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
10
0

Year Published

2002
2002
2015
2015

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 22 publications
1
10
0
Order By: Relevance
“…Also, in humans, naloxone administration has been reported to induce somatic signs of nicotine withdrawal in heavy chronic smokers (Krishnan-Sarin et al, 1999). However, these effects could be a result of, at least in part, direct blockade of nAChRs, because this opioid antagonist was found to bind nAChRs (Tome et al, 2001). Besides these pharmacological data, there are molecular studies showing a possible role of the endogenous opioid system in nicotine abstinence.…”
Section: Discussionmentioning
confidence: 99%
“…Also, in humans, naloxone administration has been reported to induce somatic signs of nicotine withdrawal in heavy chronic smokers (Krishnan-Sarin et al, 1999). However, these effects could be a result of, at least in part, direct blockade of nAChRs, because this opioid antagonist was found to bind nAChRs (Tome et al, 2001). Besides these pharmacological data, there are molecular studies showing a possible role of the endogenous opioid system in nicotine abstinence.…”
Section: Discussionmentioning
confidence: 99%
“…At the receptor level, the opioid antagonists naloxone and naltrexone have been shown to block nAChRs [123][124][125][126] (Talka, unpublished results). Naloxone and naltrexone are in clinical use for opioid intoxication and alcohol dependence [127,128].…”
Section: Nicotine Interactions With Other Opioids-experimental Evidenmentioning
confidence: 99%
“…Naloxone was even more effective than the nAChR antagonist mecamylamine in precipitating the negative emotional manifestations of nicotine withdrawal measured in the place conditioning paradigm in mice (Balerio et al, 2004). However, the opioid antagonists naloxone (Tome et al, 2001) and naltrexone (Almeida et al, 2000) also show some affinity to nAChRs, which could have some influence in the behavioral effects induced by these antagonists in nicotine-dependent animals and humans. On the other hand, the administration of MOR, DOR or KOR agonists reduces the capability of mecamylamine to produce aversive manifestations of nicotine withdrawal in the place conditioning paradigm (Ise et al 2000, 2002).…”
Section: The Role Of the Endogenous Opioid System In The Developmementioning
confidence: 99%